Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Device profile of the LithoVue single-use digital flexible ureteroscope in the removal of kidney stones: overview of safety and efficacy
Forbes, Connor M. , Lundeen, Colin , Beebe, Sarah C. , Knudsen, Bodo E. , Humphreys, Mitchell R. , Moore, Jonathan P, Moore, Jonathan P, Chew, Ben H. , Forbes, Connor M

Mayo Clinic

Expert Review of Medical Devices | December 14, 2020 | Volume: 17 | Issue: 12 | Pages: 1257-1264

10.1080/17434440.2020.1848538 | PMID 33307869 Get It

Prenatal characterization of a novel inverted SMAD2 duplication by mate pair sequencing in a fetus with dextrocardia
Zepeda‐Mendoza, Cinthya , Essendrup, Anna, Smoley, Stephanie A., Johnson, Sarah H. , Hoppman, Nicole L., Vasmatzis, George , Jackson, Daniel L. , Kearney, Hutton M. , Zepeda-Mendoza, Cinthya J , Baughn, Linda B.

Mayo Clinic

Clinical Case Reports | December 11, 2020 | Volume: 9 | Issue: 2 | Pages: 769-774

10.1002/ccr3.3608 | PMID 33598243 Get It

AbstractThis case report underlines the importance of molecular characterization of genomic duplications and other structural variants in the prenatal setting to guide clinical interpretation, genetic counseling, and perinatal medical care.
Low‐Dose Tamoxifen Induces Significant Bone Formation in Mice
McGrath, Cody , Sankaran, Jeyantt Srinivas , Styner, Maya , Little, Sarah E , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , Sen, Buer , Styner, Maya , Dudakovic, Amel , Rubin, Janet , Sen, Buer , van Wijnen, Andre J , Xie, Zhihui

Mayo Clinic

JBMR Plus | December 10, 2020 | Volume: 5 | Issue: 3 | Pages: No page available

10.1002/jbm4.10450 | PMID 33778320 Get It

ABSTRACT Use of the selective estrogen receptor modulator Tamoxifen (TAM) is a mainstay to induce conditional expression of Cre recombinase in transgenic laboratory mice. To excise β‐catenin fl/fl in 28‐day‐old male and female Prrx1‐CreER/β‐catenin fl/fl mice (C57BL/6), we utilized TAM at 150 mg/kg; despite β‐catenin knockout in MSC, we found a significant increase in trabecular and cortical bone volume in all genders. Because TAM was similarly anabolic in KO and control mice, we investigated a dose effect on bone formation by treating wild‐type mice (WT C57BL/6, 4 weeks) with TAM (total dose 0, 20, 40, 200 mg/kg via four injections). TAM increased bone in a dose‐dependent manner analyzed by micro–computed tomography (μCT), which showed that, compared to control, 20 mg/kg TAM increased femoral bone volume fraction (bone volume/total volume [BV/TV]) (21.6% ± 1.5% to 33% ± 2.5%; 153%, p < 0.005). With TAM 40 mg/kg and 200 mg/kg, BV/TV increased to 48.1% ± 4.4% (223%, p < 0.0005) and 58% ± 3.8% (269%, p < 0.0001) respectively, compared to control. Osteoblast markers increased with 200 mg/kg TAM: Dlx5 (224%, p < 0.0001), Alp (166%, p < 0.0001), Bglap (223%, p < 0.0001), and Sp7 (228%, p < 0.0001). Osteoclasts per bone surface (Oc#/BS) nearly doubled at the lowest TAM dose (20 mg/kg), but decreased to <20% control with 200 mg/kg TAM. Our data establish that use of TAM at even very low doses to excise a floxed target in postnatal mice has profound effects on trabecular and cortical bone formation. As such, TAM treatment is a major confounder in the interpretation of bone phenotypes in conditional gene knockout mouse models. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
Assessment of Pediatric Middle Ear Effusions With Wideband Tympanometry
Callaham, Sarah , Newby, Maxwell , Saoji, Aniket A. , Ramadan, Jad , Carr, Michele M.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 10, 2020 | Volume: 165 | Issue: 3 | Pages: 465-469

10.1177/0194599820978262 | PMID 33290173 Get It

ObjectiveTo determine if wideband tympanometry (WBT) can differentiate types of middle ear effusion (MEE): serous, mucoid, and purulent.Study DesignProspective cohort study.SettingTertiary care children’s hospital.MethodsChildren who met American Academy of Otolaryngology–Head and Neck Surgery’s guidelines for ventilation tube insertion had WBT after anesthesia induction but before tympanotomy. MEE was categorized into 1 of 4 comparison groups: serous effusion, mucoid effusion, purulent effusion, or no effusion. WBT measurements were averaged to 16 one‐third octave frequency bands, and comparison of the absorbance patterns for each MEE type was performed through a linear mixed effects model.ResultsA total of 118 children (211 ears) were included: 47 females (39.8%) and 71 males (60.2%). The mean age was 2.73 years (95% CI, 2.25‐3.22); mean weight, 14.35 kg (95% CI, 12.85‐15.85); and mean Z score, 1.13 (95% CI, –0.64 to 2.33). Effusions included 61 mucoid (28.9%), 30 purulent (14.2%), and 14 serous (6.6%), with 106 (50.2%) having no effusion. No significant differences were found for sex, race, age, weight, or Z score among the 4 types of effusion (P <. 05). WBT showed a significant difference in median absorption among the effusion groups (P <. 001), with a medium effect size of 0.35.ConclusionsWBT has potential use to differentiate types of MEE and should be studied further as a tool for investigating how the natural history and management of serous and mucoid effusions may differ.
Per-pass analysis of acute ischemic stroke clots: impact of stroke etiology on extracted clot area and histological composition
Fitzgerald, Seán , Rossi, Rosanna , Mereuta, Oana Madalina , Jabrah, Duaa , Okolo, Adaobi , Douglas, Andrew , Gil, Sara M. , Pandit, Abhay , McCarthy, Ray, Gilvarry, Michael , Dunker, Dennis, Nordanstig, Annika , Ceder, Erik , Redfors, Petra , Dehlfors, Niclas, Magoufis, Georgios , Brinjikji, Waleed , Kallmes, David F. , O’Hare, Alan , Power, Sarah , Brennan, Paul , Alderson, Jack , Nagy, András , Vadász, Ágnes , Szikora, István , Rentzos, Alexandros , Thornton, John , Doyle, Karen , Brinjikji, Waleed , Szikora, Istvan , Doyle, Karen M , Fitzgerald, Seán , Madalina Mereuta, Oana , Rossi, Rosanna , Jood, Katarina , Tsivgoulis, Georgios , Psychogios, Klearchos , Tatlisumak, Turgut

Mayo Clinic

Journal of NeuroInterventional Surgery | December 9, 2020 | Volume: 13 | Issue: 12 | Pages: 1111-1116

10.1136/neurintsurg-2020-016966 | PMID 33298510 Get It

Background Initial studies investigating correlations between stroke etiology and clot composition are conflicting and do not account for clot size as determined by area. Radiological studies have shown that cardioembolic strokes are associated with shorter clot lengths and lower clot burden than non-cardioembolic clots. Objective To report the relationship between stroke etiology, extracted clot area, and histological composition at each procedural pass. Methods As part of the multi-institutional RESTORE Registry, the Martius Scarlett Blue stained histological composition and extracted clot area of 612 per-pass clots retrieved from 441 patients during mechanical thrombectomy procedures were quantified. Correlations with clinical and procedural details were investigated. Results Clot composition varied significantly with procedural passes; clots retrieved in earlier passes had higher red blood cell content (H4=11.644, p=0.020) and larger extracted clot area (H4=10.730, p=0.030). Later passes were associated with significantly higher fibrin (H4=12.935, p=0.012) and platelets/other (H4=15.977, p=0.003) content and smaller extracted clot area. Large artery atherosclerotic (LAA) clots were significantly larger in the extracted clot area and more red blood cell-rich than other etiologies in passes 1–3. Cardioembolic and cryptogenic clots had similar histological composition and extracted clot area across all procedural passes. Conclusion LAA clots are larger and associated with a large red blood cell-rich extracted clot area, suggesting soft thrombus material. Cardioembolic clots are smaller in the extracted clot area, consistent in composition and area across passes, and have higher fibrin and platelets/other content than LAA clots, making them stiffer clots. The per-pass histological composition and extracted clot area of cryptogenic clots are similar to those of cardioembolic clots, suggesting similar formation mechanisms.
Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?
DiGuardo, Margaret , Kester, Sarah, Mahaffey, Victor, Hammel, Scott A., Heaser, Katelyn K., Hofich, Christopher, Tauscher, Craig D. , Kerr, Sarah E. , Oliveira, Jennifer L. , Jacob, Eapen K., Moyer, Ann M. , Herrick, Jennifer L. , DiGuardo, Margaret A , Kester, Sarah J, Mahaffey, Victor J, Hofich, Christopher D , Moyer, AM , Heaser, Kate

Mayo Clinic

Journal of Personalized Medicine | December 9, 2020 | Volume: 10 | Issue: 4 | Pages: 268

10.3390/jpm10040268 | PMID 33316904 Get It

Purpose: molecular testing is often indicated for recently transfused patients. However, there are no guidelines regarding the potential interference from donor DNA or whether it is necessary to wait for a period of time post-transfusion prior to genetic testing. While the majority of patients are transfused in the non-trauma setting using leukoreduced (LR) red blood cell products, the degree of leukoreduction varies among centers and is not universally practiced. Methods: whole blood units collected from anonymous donors were used in an in vitro transfusion model. One unit was split: half being leukoreduced simulating a leukopenic recipient and half left untreated. Donors were simulated by leukoreduced, partially leukoreduced (PLR), or non-leukoreduced units, transfused in 2, 5, or 16 unit equivalents. DNA from the combinations were subjected to short tandem repeat (STR) analysis for chimerism detection. Results: donor DNA was not detectable in any of the LR combinations, but detected in the PLR combinations, ranging from 0.1 to 1.5% donor DNA in the immunocompetent recipient and 6.3–27.8% in the leukopenic recipient. Non-LR donor DNA was also detected (13–95%). Conclusion: donor-derived DNA from leukoreduced blood products is unlikely to interfere with the interpretation of germline genetic testing in immunocompetent recipients but may interfere in immunocompromised recipients.
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Dillmon, Melissa S., Levit, Laura A. , Moushey, E. Allyn, Alva, Ajjai , Blau, Sibel , Dickson, Natalie R. , Gönen, Mithat , González, Maria Magdalena, Hensold, Jack O. , Hinyard, Leslie , King, Tari A. , Lindsey, Stacie , Magnuson, Allison , Marron, Jonathan M. , Mcaneny, Barbara , McDonnell, Theresa Margaret, Nasso, S, Nowakowski, Grzegorz S. , Oettel, Kurt R., Patel, Manali I. , Patt, Debra A. , Perlmutter, Jane , Pickard, Todd , Rodriguez, Gladys , Rosenberg, Abby R. , Russo, Barry, Szczepanek, Connie M. , Smith, Cardinale B. , Teplinsky, Eleonora , Thota, Ramya , Zoň, Robin , Bourbeau, Brian , Foster, Shelagh E., Grubbs, Stephen, Hagerty, Karen L., Hurley, Patricia A. , Kamin, Deborah Y., Phillips, Jonathan , Schilsky, Richard L. , Burris, Howard A. , Hurley, Patricia , Rosenberg, Abby R , Pennell, Nathan A , Cannon, Timothy Lewis , Diehn, Maximilian , Mileham, Kathryn Finch , Srivastava, Piyush, Traina, Tiffany A , Bruinooge, Suanna S. , Schenkel, Caroline

Mayo Clinic

Journal of Clinical Oncology | December 8, 2020 | Volume: 39 | Issue: 2 | Pages: 155-169

10.1200/jco.20.02953 | PMID 33290128 Get It

This report presents the American Society of Clinical Oncology’s (ASCO’s) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Returning negative results from large‐scale genomic screening: Experiences from the eMERGE III network
Finn, Kelsey Stuttgen , Aufox, Sharon , Bland, Harris T. , Halverson, Colin , Hebbring, Scott J. , Hoell, Christin , Jarvik, Gail P. , Leppig, Kathleen A. , Myers, Melanie F. , Prows, Cynthia A. , Rasouly, Hila Milo , Weisner, Georgia, Williams, Janet L. , Wynn, Julia , Smith, Maureen E. , Sharp, Richard R. , Halverson, Colin , Kullo, Iftikhar J , Myers, Melanie F , Sharp, Richard R , Bland, Sarah T , Milo Rasouly, Hila , Jarvik, Gail P , Hoell, Christin , Stuttgen, Kelsey , Lynch, John , Chung, Wendy K. , Holm, Ingrid A. , Kullo, Iftikhar J. , Singh, Rajbir

Mayo Clinic

American Journal of Medical Genetics Part A | December 8, 2020 | Volume: 185 | Issue: 2 | Pages: 508-516

10.1002/ajmg.a.62002 | PMID 36046768 Get It

AbstractPopulation‐based genomic screening has the potential to improve health outcomes by identifying genetic causes of disease before they occur. While much attention has been paid to supporting the needs of the small percentage of patients who will receive a life‐altering positive genomic screening result that requires medical attention, little attention has been given to the communication of negative screening results. As there are currently no best practices for returning negative genomic screening results, we drew on experiences across the electronic medical records and genomics (eMERGE) III Network to highlight the diversity of reporting methods employed, challenges encountered in reporting negative test results, and “lessons learned” across institutions. A 60‐item survey that consisted of both multiple choice and open‐ended questions was created to gather data across institutions. Even though institutions independently developed procedures for reporting negative results, and had very different study populations, we identified several similarities of approach, including but not limited to: returning results by mail, placing results in the electronic health record via an automated process, reporting results to participants' primary care provider, and providing genetic counseling to interested patients at no cost. Differences in procedures for reporting negative results included: differences in terminology used to describe negative results, definitions of negative results, guidance regarding the meaning of negative results for participants and their family members, and recommendations for clinical follow up. Our findings highlight emerging practices for reporting negative genomic screening results and highlight the need to create patient education and clinical support tools for reporting negative screening results.
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, Shaji , Adekola, Kehinde , Anderson, Larry D. , Castillo, Jorge J. , Chandler, Jason C., Costello, Caitlin , Efebera, Yvonne A. , Faiman, Matthew , Garfall, Alfred L. , Godby, Kelly, Hillengaß, Jens , Holmberg, Leona , Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Larson, Sarah , Liedtke, Michaela , Omel, James, Shain, Kenneth H. , Sborov, Douglas W. , Stockerl‐Goldstein, Keith , Weber, Donna, Keller, Jennifer , Holmberg, Leona , Castillo, Jorge J , Anderson, Larry D , Garfall, Alfred L , Callander, Natalie S. , Baljević, Muhamed , Campagnaro, Erica , Kang, Yubin , Martin, Thomas G. , Kumar, Rashmi , Stockerl-Goldstein, Keith

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1685-1717

10.6004/jnccn.2020.0057 | PMID 33285522 Get It

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.
NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021
Kane, John M. , Connelly, Mary, Ganjoo, Kristen N. , Heslin, Martin J. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Meyer, Christian F. , Pappo, Alberto S. , Paz, I. Benjamin , Petersen, Ivy A. , Poppe, Matthew M. , Riedel, Richard F. , Schuetze, Scott M. , Shabason, Jacob E. , Bergman, Mary Anne, George, Giby V. , Riedel, Richard F , Mehren, Margaret von , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , George, Suzanne , González, Ricardo , Liebner, David A. , Parkes, Amanda , Rubin, Brian P. , Sicklick, Jason Keith , Spraker, Matthew B. , Zimel, Melissa N.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 7, 2020 | Volume: 18 | Issue: 12 | Pages: 1604-1612

10.6004/jnccn.2020.0058 | PMID 33285515 Get It

The NCCN Guidelines for Soft Tissue Sarcoma provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with soft tissue sarcomas. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including the development of a separate and distinct guideline for gastrointestinal stromal tumors (GISTs); reconception of the management of desmoid tumors; inclusion of further recommendations for the diagnosis and management of extremity/body wall, head/neck sarcomas, and retroperitoneal sarcomas; modification and addition of systemic therapy regimens for sarcoma subtypes; and revision of the principles of radiation therapy for soft tissue sarcomas.